Clinical Potential of Prefusion RSV F-specific Antibodies
- PMID: 29054341
- DOI: 10.1016/j.tim.2017.09.009
Clinical Potential of Prefusion RSV F-specific Antibodies
Abstract
Human respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infections in the very young. The RSV fusion protein (F) is essential for virus entry because it mediates viral and host membrane fusion. During this fusion process F is converted from a metastable prefusion conformation into an energetically favored postfusion state. Antibodies that target F can prevent viral entry and reduce disease caused by RSV. During recent years, many prefusion F-specific antibodies have been described. These antibodies typically have stronger RSV-neutralizing activity compared to those that also bind F in the postfusion conformation. Here, we describe how F-specific antibodies protect against RSV and why specifically targeting prefusion F could have great clinical potential.
Keywords: RSV; fusion protein; monoclonal antibodies.
Copyright © 2017 Elsevier Ltd. All rights reserved.
Similar articles
-
Enhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine Candidate.J Virol. 2015 Sep;89(18):9499-510. doi: 10.1128/JVI.01373-15. Epub 2015 Jul 8. J Virol. 2015. PMID: 26157122 Free PMC article.
-
Alternative Virus-Like Particle-Associated Prefusion F Proteins as Maternal Vaccines for Respiratory Syncytial Virus.J Virol. 2019 Nov 13;93(23):e00914-19. doi: 10.1128/JVI.00914-19. Print 2019 Dec 1. J Virol. 2019. PMID: 31511382 Free PMC article.
-
Packaging and Prefusion Stabilization Separately and Additively Increase the Quantity and Quality of Respiratory Syncytial Virus (RSV)-Neutralizing Antibodies Induced by an RSV Fusion Protein Expressed by a Parainfluenza Virus Vector.J Virol. 2016 Oct 14;90(21):10022-10038. doi: 10.1128/JVI.01196-16. Print 2016 Nov 1. J Virol. 2016. PMID: 27581977 Free PMC article.
-
Human respiratory syncytial virus: pathogenesis, immune responses, and current vaccine approaches.Eur J Clin Microbiol Infect Dis. 2018 Oct;37(10):1817-1827. doi: 10.1007/s10096-018-3289-4. Epub 2018 Jun 6. Eur J Clin Microbiol Infect Dis. 2018. PMID: 29876771 Review.
-
Neutralizing epitopes on the respiratory syncytial virus fusion glycoprotein.Curr Opin Virol. 2015 Apr;11:70-5. doi: 10.1016/j.coviro.2015.03.002. Epub 2015 Mar 26. Curr Opin Virol. 2015. PMID: 25819327 Free PMC article. Review.
Cited by
-
Engineered dityrosine-bonding of the RSV prefusion F protein imparts stability and potency advantages.Nat Commun. 2024 Mar 14;15(1):2202. doi: 10.1038/s41467-024-46295-8. Nat Commun. 2024. PMID: 38485927 Free PMC article.
-
Development and comparison of immunologic assays to detect primary RSV infections in infants.Front Immunol. 2024 Jan 12;14:1332772. doi: 10.3389/fimmu.2023.1332772. eCollection 2023. Front Immunol. 2024. PMID: 38283339 Free PMC article.
-
Bivalent vaccines effectively protect mice against influenza A and respiratory syncytial viruses.Emerg Microbes Infect. 2023 Dec;12(1):2192821. doi: 10.1080/22221751.2023.2192821. Emerg Microbes Infect. 2023. PMID: 36927227 Free PMC article.
-
A human antibody potently neutralizes RSV by targeting the conserved hydrophobic region of prefusion F.Sci China Life Sci. 2023 Apr;66(4):729-742. doi: 10.1007/s11427-022-2250-0. Epub 2023 Feb 23. Sci China Life Sci. 2023. PMID: 36853487 Free PMC article.
-
Antibody Correlates of Protection From Severe Respiratory Syncytial Virus Disease in a Vaccine Efficacy Trial.Open Forum Infect Dis. 2023 Jan 12;10(1):ofac693. doi: 10.1093/ofid/ofac693. eCollection 2023 Jan. Open Forum Infect Dis. 2023. PMID: 36655191 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
